Assenagon Asset Management
RCKT icon

Assenagon Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Assenagon Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
84,815
-14,211
-14% -$47.3K ﹤0.01% 1121
2026
Q1 		$355K Buy
99,026
+66,511
+205% +$264K ﹤0.01% 1034
2025
Q4 		$114K Sell
32,515
-3,301
-9% -$11.3K ﹤0.01% 1133
2025
Q3 		$117K Buy
+35,816
New +$113K ﹤0.01% 1147
2024
Q3 		– Sell
-29,986
Closed -$646K – 1455
2024
Q2 		$646K Sell
29,986
-50,740
-63% -$1.17M ﹤0.01% 1193
2024
Q1 		$2.17M Sell
80,726
-621,899
-89% -$17.7M 0.01% 866
2023
Q4 		$21.1M Sell
702,625
-174,515
-20% -$3.85M 0.06% 281
2023
Q3 		$18M Buy
877,140
+449,569
+105% +$8.17M 0.06% 270
2023
Q2 		$8.5M Sell
427,571
-5,017
-1% -$101K 0.03% 384
2023
Q1 		$7.41M Sell
432,588
-572,734
-57% -$11.2M 0.03% 459
2022
Q4 		$19.7M Sell
1,005,322
-379,612
-27% -$6.99M 0.07% 245
2022
Q3 		$22.1M Sell
1,384,934
-308,828
-18% -$4.82M 0.08% 232
2022
Q2 		$23.3M Buy
1,693,762
+373,201
+28% +$4.45M 0.09% 203
2022
Q1 		$20.9M Buy
1,320,561
+783,621
+146% +$13.5M 0.06% 238
2021
Q4 		$11.7M Buy
536,940
+507,588
+1,729% +$13.8M 0.03% 297
2021
Q3 		$877K Sell
29,352
-6,359
-18% -$231K ﹤0.01% 940
2021
Q2 		$1.58M Sell
35,711
-161
-0.4% -$6.99K 0.01% 764
2021
Q1 		$1.59M Sell
35,872
-8,428
-19% -$463K 0.01% 768
2020
Q4 		$2.43M Sell
44,300
-300,429
-87% -$11M 0.01% 484
2020
Q3 		$7.88M Sell
344,729
-147,637
-30% -$3.64M 0.04% 244
2020
Q2 		$10.3M Buy
+492,366
New +$8.88M 0.07% 184
2019
Q3 		– Sell
-230,342
Closed -$3.46M – 1034
2019
Q2 		$3.46M Buy
230,342
+170,775
+287% +$2.98M 0.03% 377
2019
Q1 		$1.04M Buy
59,567
+14,961
+34% +$236K 0.01% 675
2018
Q4 		$661K Buy
+44,606
New +$741K 0.01% 761

Other funds holding RCKT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Assenagon Asset Management's RCKT Position: Q2 2026 in Review

Assenagon Asset Management reduced its Rocket Pharmaceuticals (RCKT) stake by 14% in Q2 2026, selling an estimated $47.3K and leaving 84,815 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Assenagon Asset Management first reported a position in RCKT in Q4 2018 and has held it in 24 quarters since. The position peaked at $23.3M in Q2 2022. 14 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Assenagon Asset Management held 84,815 shares of Rocket Pharmaceuticals worth $290K as of Q2 2026.
  • Assenagon Asset Management sold 14,211 Rocket Pharmaceuticals shares in Q2 2026, an estimated $47.3K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1121 holding.
  • Assenagon Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • Assenagon Asset Management's Rocket Pharmaceuticals position peaked at $23.3M in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.